HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials.
John P. Neoptolemos(University of Liverpool), Julia Mayerle(LMU Klinikum), Alec McDonald(Beatson West of Scotland Cancer Centre), Charlotte Rawcliffe(University of Liverpool), Elizabeth O. Garner(University of Liverpool), Paula Ghaneh(University of Liverpool), F Lacaine(Sorbonne Université), Daniel H. Palmer(University of Liverpool), William Greenhalf(University of Liverpool), John R. Mackey(University of Alberta), Markus W. Büchler(Heidelberg University), Bengt Glimelius(Uppsala University), Richard Charnley(Newcastle upon Tyne Hospitals NHS Foundation Trust), Claudio Bassi(University of Verona), Juan W. Valle(Cancer Research UK Manchester Institute), Niall C. Tebbutt(Austin Health), Trevor F. Cox(University of Liverpool), Fiona Campbell(University of Birmingham), Malcolm J. Moore(University Health Network), Christos Dervenis(Agia Olga Hospital)
Cited by 17
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k